ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements with these filters
Aurobindo Pharma disclosed that US FDA classified its Lannett facility inspection as Official Action Indicated (OAI). The company states there is no quantifiable financial or operational impact.
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.
Aurobindo Pharma reported Q2 FY27 revenue of Rs.10,263 Crore, up 23.9% YoY, and net profit of Rs.1,124 Crore. An interim dividend of Rs.7 per share was declared.
Aurobindo Pharma Ltd reported revenue from operations of ₹10,263 Cr (+23.9% YoY) and net profit of ₹1,124 Cr (+32.5% YoY) for Q2 FY27.
Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.
Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.
Aurobindo Pharma received an order from the Appellate Joint Commissioner regarding an ITC demand, interest, and penalty totaling ₹4.60 Crore.
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.